Regenxbio (RGNX) call put ratio 5.2 calls to 1 put with a focus on August 12 calls

Wed, 22 Jul 2026 03:58:15 -0400

Regenxbio (NASDAQ: RGNX) 30-day call option implied volatility is 101; compared to its 52-week range of 52 to 263. Call put ratio 5.2 calls to 1 put with a focus on August 12 calls.

Form 8-K REGENXBIO Inc. For: Jul 16

Mon, 20 Jul 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260720/26787089.html

Form 8-K REGENXBIO Inc. For: Jul 16

Mon, 20 Jul 2026 07:34:00 -0400

si-local-file:///var/storage/secattach/20260720/26787089.html

Regenxbio shares long-term gene therapy data for eye diseases

Mon, 20 Jul 2026 03:19:46 -0400

Regenxbio Inc. (Nasdaq: RGNX) presented long-term follow-up data for its investigational gene therapy surabgene lomparvovec (sura-vec) in wet age-related macular degeneration (AMD) and diabetic retinopathy (DR) at the American Society of Retina Specialists 44th Annual Meeting in Montreal, Canada.

In wet AMD, participants in Cohorts 3 and 4 of a Phase I/IIa trial who received a single subretinal administration of sura-vec at doses similar to those used in the ongoing ATMOSPHERE and ASCENT pivotal trials showed stable to improved visual acuity and reduced anti-VEGF injection burden through five years. No intraocular inflammation was observed in long-term follow-up. A separate external control

Regenxbio shares long-term gene therapy data for eye diseases

Mon, 20 Jul 2026 03:19:46 -0400

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Sat, 18 Jul 2026 14:55:00 -0400

One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies:
- Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec; no drug-related IOI observed in a setting of no prophylactic steroids
- Prevention of vision-threatening events without any additional treatment and >2-step DRSS improvement in majority of NPDR participants at 2.5 years; no IOI observed with short-course prophylactic topical steroids
Topline data from wet AMD pivotal studies, ATMOSPHERE^® and ASCENT^®, expected in Q4 2026

ROCKVILLE, Md.,,

Form 424B5 REGENXBIO Inc.

Fri, 17 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26785273.html

Form 424B5 REGENXBIO Inc.

Fri, 17 Jul 2026 17:30:00 -0400

si-local-file:///var/storage/secattach/20260717/26785273.html

Regenxbio prices $100M public offering of stock and warrants